EchoGo Amyloidosis vs Merlin.net
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is an AI-powered diagnostic screening tool for cardiac amyloidosis, analyzing echocardiogram video clips to aid in early detection. In contrast, Merlin.net is a remote monitoring platform designed for managing data from patients with Abbott implanted cardiac devices. While both operate in cardiology and are cloud-based, they serve distinct purposes: one for disease detection and the other for ongoing patient and device management.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. Merlin.net Patient Care Network is a web-based remote monitoring platform for clinicians to manage data from patients with implanted cardiac devices, enabling remote follow-up and device performance monitoring.
EchoGo Amyloidosis analyzes echocardiogram video clips, specifically looking at echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement. Merlin.net analyzes data from Abbott implanted cardiac devices, providing insights into device performance and clinical trends.
EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. Merlin.net features EHRDirectu2122 data transfer for seamless EHR integration, utilizing HL7 standards.
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis. Merlin.net offers features like DirectAlertsu2122 for patient events, SmartScheduleu2122 for follow-up coordination, and a DirectTrendu2122 viewer for dynamic device and clinical trends.
Yes, for EchoGo Amyloidosis, an NTAP Code (ICD-10 XXE2X19) is available for inpatient analysis ($1,000, Medicare-covered), and a HCPCS Code (C9786) for outpatient analysis ($285, covered by Medicare and select commercial insurers). For Merlin.net, pricing information requires contacting the vendor.
EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity. It also shows consistent performance across various cardiac amyloidosis subtypes, including AL, wild-type ATTR, and variant ATTR.